Abstract
Gabriella Yongue, Zachary Nash, Kristyn Manley, Melanie C Davies, Shibani Nicum
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
The role of lifestyle medicine in menopausal health: a review of non-pharmacologic interventions
10.1080/13697137.2025.2548806 · 2025
Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial
10.1097/gme.0b013e31823fe835 · 2012
Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis
10.1210/jc.2019-00192 · 2019
Evaluating the efficacy of vaginal for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (alliance)
2018
Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer
10.1097/gme.0b013e31826560da · 2013
Integrating menopause care into oncology: implementation of a multidisciplinary oncology–menopause meeting for gynaecological cancer survivors
10.1016/j.ijgc.2025.103161 · 2026
Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer
10.1007/s10549-015-3511-3 · 2015
Gonadotropin-releasing hormone and its analogues
10.1056/nejm199101103240205 · 1991
Gut-brain communication in menopause: insights into neuroendocrine and microbiome interactions
10.1017/s0029665126102201 · 2026
The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy
10.1210/jc.2009-1523 · 2009
Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part I: evaluation of efficacy
10.1016/j.maturitas.2018.11.016 · 2019
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
10.1016/s0140-6736(15)60908-4 · 2015
Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC–MS/MS (liquid chromatography–tandem mass spectrometry) method for estrogen measurement
10.1007/s10549-023-07054-3 · 2023
Cardiovascular disease risk among cancer survivors
10.1016/j.jacc.2022.04.042 · 2022
Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study
10.1007/s10549-007-9523-x · 2007
Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers
10.1016/j.bpobgyn.2020.01.006 · 2020
Association of age at menopause and duration of reproductive period with depression after menopause: a systematic review and meta-analysis
10.1001/jamapsychiatry.2015.2653 · 2016
Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study
10.1016/j.ygyno.2021.10.001 · 2021
Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment
10.1093/annonc/mdl030 · 2006
The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis
10.1080/13697137.2019.1574738 · 2019
Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
10.6004/jnccn.2026.0033 · 2026
Managing menopause after cancer
10.1016/s0140-6736(23)02802-7 · 2024
What happens after menopause? (WHAM): a prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy
10.1016/j.ygyno.2021.07.029 · 2021
PERCEIVE: a retrospective, qualitative interview-based study of the impact of vasomotor symptoms associated with menopause on the lives of individuals who are not suitable candidates for hormone therapy
10.1016/j.maturitas.2025.108670 · 2025
Does a multidisciplinary menopausal symptoms after cancer clinic reduce symptoms?
2022
Unresolved referenced work
Kept as external metadata until matched
Biology and receptor interactions of estriol and estriol derivatives in vitro and in vivo
1984
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial
10.1016/s1470-2045(08)70341-3 · 2009
Applying a life course biological age framework to improving the care of individuals with adult cancers: review and research recommendations
10.1001/jamaoncol.2021.1160 · 2021
Nature and severity of menopausal symptoms and their impact on quality of life and sexual function in cancer survivors compared with women without a cancer history
10.1097/gme.0b013e3182976f46 · 2014
The menopause specialist and breast cancer survivorship
10.1177/2053369116668738 · 2016
Toxicity of chemotherapy and radiation on female reproduction
10.1097/grf.0b013e3181f96b54 · 2010
Menopause care: alternatives to hormone replacement therapy
10.1111/tog.70010 · 2025
Aromatase inhibitors as adjuvant therapy in early breast cancer: insights into toxicities and their management
10.3390/cancers17172726 · 2025
Top ten menopause research priorities
10.1016/s0140-6736(24)02602-3 · 2024
Menopause: management – management of menopause, perimenopause, or premature ovarian insufficiency
Kept as external metadata until matched
DailyMed: SOLTAMOX – tamoxifen citrate liquid
Kept as external metadata until matched
Evidence-based guideline: premature ovarian insufficiency
10.1093/hropen/hoae065 · 2024
Experiencing menopause in the context of cancer: women’s constructions of gendered subjectivities
10.1080/08870446.2017.1320799 · 2017
Who is managing menopausal symptoms, sexual problems, mood and sleep disturbance after breast cancer and is it working? Findings from a large community-based survey of breast cancer survivors
10.1007/s10549-021-06117-7 · 2021
Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: pooled analysis of individual data from 10 international studies
10.1093/humrep/deaa124 · doi-reference
Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data
10.1016/s2468-2667(19)30155-0 · doi-reference
Association between premature ovarian insufficiency and biological aging
10.1093/ejendo/lvaf102 · doi-reference
Vitamin D concentration among women with gynecological cancers
10.3390/cancers17121987 · doi-reference
Positive impact of a co-designed digital resource for women with early menopause
10.1097/gme.0000000000001972 · doi-reference
Fracture risk prediction using the fracture risk assessment tool in individuals with cancer
10.1001/jamaoncol.2024.4318 · doi-reference
Fertility preservation for young patients with cancer: who is at risk and what can be offered?
10.1016/s1470-2045(05)70092-9 · doi-reference
Complications of pelvic radiation in patients treated for gynecologic malignancies
10.1002/cncr.28849 · doi-reference
Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases
10.1136/bmj.k4810 · doi-reference
Association of muscle disorders in late postmenopausal women according to the type of experienced menopause
10.1097/gme.0000000000002367 · doi-reference
Endogenous hormones and risk of invasive breast cancer in pre- and post-menopausal women: findings from the UK Biobank
10.1038/s41416-021-01392-z · doi-reference
10.1177/20533691241286666
10.1177/20533691241286666 · doi-reference
Safety and efficacy of topical testosterone in breast cancer patients receiving ovarian suppression and aromatase inhibitor therapy
10.1186/s13058-024-01886-7 · doi-reference
Effect of primary ovarian insufficiency and early natural menopause on mortality: a meta-analysis
10.3109/13697137.2015.1094784 · doi-reference
Effects of self-reported age at nonsurgical menopause on time to first fracture and bone mineral density in the Women’s Health Initiative Observational Study
10.1097/gme.0000000000000451 · doi-reference
The silent grief: psychosocial aspects of premature ovarian failure
10.3109/13697137.2011.571320 · doi-reference
The role of cyclin-dependent kinases (CDK) 4/6 in the ovarian tissue and the possible effects of their exogenous inhibition
10.3390/cancers15204923 · doi-reference
Chemobrain and cancer survivorship: a scoping review of the literature
10.1002/cam4.71383 · doi-reference
Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause
10.1212/01.wnl.0000276984.19542.e6 · doi-reference
Hormone replacement therapy and the risk of venous thromboembolism: a population-based study
10.1111/j.1538-7836.2010.03839.x · doi-reference
Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement
10.1210/jc.2013-4145 · doi-reference